NCCN Guidelines for Patients® | Diffuse Large B-cell Lymphoma

41 NCCN Guidelines for Patients ® : Diffuse Large B-cell Lymphoma, 2017 Drug regimens Combinations of drugs are almost always used to treat DLBCL. These combinations can be complex. Throughout Part 4, the short names for the regimens are listed. Below, the name of each drug for every regimen is provided. † † CEOP (cyclophosphamide, etoposide, vincristine, prednisone) † † CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) † † DHAP (dexamethasone, cisplatin, cytarabine) † † Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) † † ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) † † GDP [gemcitabine, dexamethasone, (cisplatin or carboplatin)] † † GemOx (gemcitabine, oxaliplatin) † † ICE (ifosfamide, carboplatin, etoposide) † † MINE (mesna, ifosfamide, mitoxantrone, etoposide) † † RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) † † RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone) † † RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine) † † RCDOP (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) † † RGCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) During and after cancer treatment, you may be treated to prevent or control other health conditions. Such actions are a part of supportive care. Health conditions that are a concern for some people include TLS, reactivated viruses, and other infections. Talk to your doctor about which health conditions you may develop as a result of cancer treatment. 4 Treatment guide First-line treatment